The Vytorin on Carotid Intima‐Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This study assessed the effect of 3 lipid‐lowering therapies on the reduction of the carotid intima‐media thickness (IMT) in high‐risk coronary Mexican patients. The study was a randomized, comparative, and open clinical trial. Ninety high‐risk coronary patients were allocated to 3 groups: pravastatin 40 mg, simvastatin 40 mg, and simvastatin 20 mg and ezetimibe 10 mg initially. If the therapeutic goals were not attained (<100 mg/dL of low‐density lipoprotein cholesterol [LDL‐C] for type C and <70 mg for type D), patients in group 1 received pravastatin 40 mg and ezetimibe 10 mg, group 2 received simvastatin 80 mg, and group 3 received simvastatin 40 mg and ezetimibe 10 mg. The primary endpoint was the change of IMT over the course of 1 year. The secondary endpoints were changes in LDL‐C and in high sensitive C‐reactive protein (CRPhs). The overall baseline IMTs generated by combining measurements in the internal carotid artery were 1.33 ± 0.32 mm, 1.30 ± 0.11 mm, and 1.23 ± 0.28 mm for groups 1, 2, and 3, respectively. After 1 year, IMT values were 0.93 ± 0.13 mm, 0.90 ± 0.11 mm, and 0.92 ± 0.01 mm for groups 1, 2, and 3, respectively. At the end of the study, LDL‐C levels were 48 ± 41, 45 ± 37, and 48 ± 31 in groups 1, 2, and 3, respectively. No significant differences were observed in CRP, high‐density lipoprotein cholesterol, triglycerides, blood pressure, and body mass index, among the groups. This study is one of the first providing evidence that dual therapy has a beneficial effect on a surrogate marker of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
Available, N. (2000) · JAMA · doi:10.1001/jama.284.23.3043 · Cited by 2,344
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · cited 1×
“Even before the statins era, several trials had shown that rather modest reductions in TC and LDL-C significantly improved coronary and cardiovascular prognosis.(40,41) With the use of statins, the evidence for this claim grew further.”
ResultSimvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Beneficial Cardiovascular Pleiotropic Effects of Statins
Davignon, J. (2004) · Circulation · doi:10.1161/01.cir.0000131517.20177.5a · Cited by 955
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
Sudhop, T., Lütjohann, D., Kodal, A., Igel, M., Tribble, D. L., Shah, S., Perevozskaya, I., & von Bergmann, K. (2002) · Circulation · doi:10.1161/01.cir.0000034044.95911.dc · Cited by 682
Cited by
Ezetimibe therapy: mechanism of action and clinical update
Toth, P., Phan, & Dayspring, T. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 288
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502.pub2 · Cited by 109
Huang, Y., Li, W., Dong, L., Li, R., & Wu, Y. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14001 · Cited by 76
Chan, D. C., & Watts, G. F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.502529 · Cited by 69
“Recent data from the Framingham Heart Study show that the prevalence of MetS almost doubled after 10 years of follow-up (from 23.5 to 40.6”
BackgroundInfluentialNiemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases
Pirillo, A., L. Catapano, A., & D. Norata, G. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160229114111 · Cited by 45
Metadata
- Authors
- Meaney, A., Ceballos, G., Asbun, J., Solache, G., Mendoza, E., Vela, A., & Meaney, E.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-07
- Volume
- 49
- Issue
- 7
- Pages
- 838-847
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2132162389
- Cited by
- 75
- References
- 11
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Vytorin on Carotid Intima‐Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. https://app.cochat.ai/papers/10.1177/0091270009337011
- The paper
- Meaney, A., Ceballos, G., Asbun, J., Solache, G., Mendoza, E., Vela, A., & Meaney, E. (2009). The Vytorin on Carotid Intima‐Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009337011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.